検索キーワード： 著者 "Annenberg Center for Health Sciences" すべてのカテゴリー

The treatment of persons with hemophilia continues to evolve, with important advancements that address limitations with factor replacement such as diminished efficacy in patients with inhibitors and the burden of frequent intravenous administration. This 30-minute activity delves into the latest research presented at ISTH 2025, highlighting rebalancing agents and factor VIII mimetics. In addition to discussing details of each trial, Dr. von Drygalski shares her thoughts about its importance and relevance to clinical practice.

It's often been said that ‘Obesity is a choice, not disease,’ ‘Low fat diets are the best way to reduce body fat’ or that ‘Weight loss of at least 10% is needed for any benefit.’ The truth is these are false. In this series, Dr. Holly Lofton unpacks the truth and provides practical advice about 14 myths and misconceptions, so that people with obesity can better manage this chronic disease with support from their healthcare team. Won’t you join Dr. Lofton? It’s time to set the record straight and replace myths and misconceptions with truth – and turn challenges into ...

Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists Lucio Gordan, MD, and Saby George, MD, discuss the burden of IV ICIs, how subcutaneous options address these issues, compare efficacy and safety, and highlight the role of multidisciplinary teams in treatment decisions and workflow optimization.

The management of persons with obesity is challenging, made even greater due to the numerous myths and misconceptions among patients and clinicians. For example, “Obesity is a choice, not a disease.” “Weight loss of at least 10% is needed for any health benefit.” “Drugs should not be used because weight will only be regained once they are discontinued.” Science and clinical experience, however, tell us otherwise.

Gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection are significant gastrointestinal challenges that impact patient quality of life, requiring proper diagnosis and treatment. In this 60-minute, case-based educational activity, multidisciplinary faculty guide clinicians through contemporary diagnostic techniques and evidence-based treatment strategies for both nonerosive and erosive GERD, as well as H. pylori infection.

Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.

John Colombo, PhD, answers questions related to infant brain development and cognition. Fayez K. Ghishan, MD answers questions related to Milk Fat Globule Membrane (MFGM) Sean C.L. Deoni, PhD answers questions related to Docosahexaenoic acid (DHA)

In the first few weeks of life, the optimal growth rate for preterm infants is nearly twice that of term infants. To achieve this rapid rate of growth, preterm infants have high energy, protein, and micronutrient requirements. However, variability in human milk composition and inadequate fortification practices often result in suboptimal nutrition intake during these early critical weeks.

The gut microbiome is recognized as playing a key role in infant health. Alessio Fasano, MD, world-renowned for his research on the gut microbiome focuses on the ways in which the gut microbiome influences allergy and autoimmunity. The effects of infant nutrition on the composition of the microbiome are also discussed, including the impact of feeding mode and probiotic and prebiotic supplementation.

Renowned professor of pediatric gastroenterology and nutrition, and endowed chair in pediatric research, Fayez K. Ghishan, MD, discusses the important role gastrointestinal microbiota plays in the development of immune function.

Anna Nowak-Wegrzyn, MD, PhD, takes a case-based approach to identify and diagnose food protein-induced enterocolitis syndrome (FPIES) in infants and how to manage acute reactions.

Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, FACS, moderates this series of six, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty review the current understanding of the burden and pathophysiology of thyroid eye disease—including ...

In this in-depth review, presented by Princess Ogbogu, MD, and developed in collaboration with Michael Wechsler, MD, MMSc, the wide-ranging presentations of HES will be reviewed, along with pathophysiology, classification, and acute and chronic management. Learnings from the presentation will be tied together with a case-based presentation of idiopathic HES, allowing learners to see how guideline recommendations and novel clinical trials can be applied in a real clinical setting.

Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understanding of the pathogenesis of this disorder caused by cold-reacting IgM autoantibodies and reveal common clinical features. Because of the high mortality rate among those suffering from CAD, it is important to be aware of the diagnostic criteria, as well as the current and novel treatment options, with the goal of increasing hemoglobin levels, avoiding the need for transfusions, and improving ...

In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.

Obesity experts Drs. Apovian and Kushner delve into the complex and undertreated disease of obesity, addressing the importance of weight loss and chronic weight management. They discuss obesity as a chronic disease with its pathophysiologic basis, associated cardiometabolic risks, treatment options including pharmacotherapy, focusing on incretin-based medications, optimizing weight loss and maintenance, and how to approach patients about obesity.

Human breast milk is comprised of several bioactive components, including human milk oligosaccharides (HMOs), which are non-nutritive carbohydrates unique to human milk. In this course, Lars Bode, PhD, introduces HMOs and describes the structure, composition, and infant health benefits of these compounds. Topics include the prebiotic effects of HMOs, particularly related to the gastrointestinal and immune systems, but also growth and development and allergies. Also reviewed are the oligosaccharides found in infant formulas, with a focus on clinically relevant inform

Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disorder that causes accumulation of sphingomyelin in various organs. In addition to a low incidence, ASMD has a heterogeneous presentation that makes management challenging. Join experts Margaret McGovern, MD, PhD, and Pramod Mistry, MD, PhD, in this review of the diagnosis and treatment of patients with ASMD.

Managing food allergies is challenging for caregivers, and it is difficult for busy clinicians to keep up with evolving guidelines on this topic. However, knowledge of recent research and recommendations for food allergy management is essential for pediatric clinicians to provide appropriate guidance and referrals for affected families.

Pruritus occurs in up to 70% of patients with primary biliary cholangitis (PBC), can be severe, and lead to increased morbidity-including worsening fatigue and quality of sleep. Standard of care treatment has relied on a variety of medications with limited effectiveness and tolerability adding to the patient disease burden. Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team.